Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
4.585
+0.145 (3.27%)
Aug 12, 2025, 3:41 PM - Market open

Company Description

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.

The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.

It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors.

It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Cellectar Biosciences, Inc.
Cellectar Biosciences logo
CountryUnited States
Founded2002
IndustryBiotechnology
SectorHealthcare
Employees11
CEOJames Caruso

Contact Details

Address:
100 Campus Drive
Florham Park, New Jersey 07932
United States
Phone608 441 8120
Websitecellectar.com

Stock Details

Ticker SymbolCLRB
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001279704
CUSIP Number15117F880
ISIN NumberUS15117F8804
Employer ID04-3321804
SIC Code2834

Key Executives

NamePosition
James V. CarusoPresident, Chief Executive Officer and Director
Chad J. Kolean CPAVice President, Chief Financial Officer and Secretary
Jarrod LongcorChief Operating Officer

Latest SEC Filings

DateTypeTitle
Aug 8, 2025SCHEDULE 13GFiling
Jul 8, 2025SCHEDULE 13GFiling
Jul 2, 2025424B4Prospectus
Jul 1, 2025EFFECTNotice of Effectiveness
Jun 30, 2025S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Jun 26, 20258-KCurrent Report
Jun 26, 2025S-1General form for registration of securities under the Securities Act of 1933
Jun 25, 20258-KCurrent Report
Jun 18, 20258-KCurrent Report
Jun 13, 20258-KCurrent Report